7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Nuvalent, Inc.
(NASDAQ:NUVL) 

NUVL stock logo

Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant muta...

Founded: 2017
CEO: James Porter  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Nuvalent . Number of Twitter Followers
202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 049.8699.71149.57199.43249.29299.14349
Nuvalent . Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.96-1.68-1.4-1.12-0.84-0.56-0.280
Nuvalent . Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.96-1.68-1.4-1.12-0.84-0.56-0.280
Nuvalent . Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01.653.314.966.628.279.9211.58
Nuvalent . (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -48.47-41.54-34.62-27.7-20.77-13.85-6.920
Nuvalent . P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01.83.595.397.188.9810.7712.57
No extra charts and metrics for this ticker.